Suggested remit - To appraise the clinical and cost effectiveness of lenadogene nolparvovec within its marketing authorisation for treating Leber's hereditary optic neuropathy
Please note that following on from information received from the company, NICE has decided to suspend this evaluation from its current work programme. The timelines for this evaluation are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this evaluation will be available in due course.
- Status:
- Suspended
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1410
Project Team
- Project lead
- Daniel Davies
Email enquiries
If you have any queries please email TATeam3@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 13 June 2023 | Suspended. Please note that following on from information received from the company, NICE has decided to suspend this evaluation from its current work programme. The timelines for this evaluation are to be aligned with the latest regulatory and UK launch expectations and further information regarding the scheduling of this evaluation will be available in due course. |
| 07 February 2023 | Invitation to participate |
| 07 November 2022 - 07 December 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 05 July 2022 | Note added to the project documents |
| 11 May 2022 | Note added to the project documents |
| 21 June 2021 - 02 July 2021 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 21 June 2021 | Note added to the project documents |
| 01 September 2020 | In progress. Topic is in progress |
| 01 September 2020 | Note added to the project documents |
| 25 September 2018 - 23 October 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
For further information on our processes and methods, please see our CHTE processes and methods manual